DAFTAR PUSTAKA

Azzi, A., Breyer, I., Feher, M., Pastori, M., Ricciarelli, R., Spycher, S., et al (2018). *Recent Advances in Nutritional Sciences*. *April*, 1649–1652.

Chen, P., Qin, L., Li, G., Wang, Z., Dahlman, J. E., Malagon-lopez, J., Gujja, S., Cilfone, N. A., Kauffman, K. J., Kusters, P.,et al (2022). inflammation and atherosclerosis. *Nature Metabolism*. https://doi.org/10.1038/s42255-019-0102-3

Cipollone, F., Mezzetti, A., Fazia, M. L., Cuccurullo, C., Iezzi, A., Occhino, S., Spigonardo, F., Bucci, M., et al (2005). Association between 5-lipoxygenase expression and plaque instability in humans. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *25*(8), 1665–1670. https://doi.org/10.1161/01.ATV.0000172632.96987.2d

Colazzo, F., Gelosa, P., Tremoli, E., Sironi, L., & Castiglioni, L. (2017a). Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases. *Mediators of Inflammation*, *2017*(Figure 1). https://doi.org/10.1155/2017/2432958

Colazzo, F., Gelosa, P., Tremoli, E., Sironi, L., & Castiglioni, L. (2017b). Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases. *Mediators of Inflammation*, *2017*(Figure 1). https://doi.org/10.1155/2017/2432958

Crosslin, D. R., Shah, S. H., Nelson, S. C., Haynes, C. S., Connelly, J. J., Gadson, S., Goldschmidt-Clermont, P. J., Vance, J. M., Rose, J., Granger, C. B., Seo, D., Gregory, S. G., Kraus, W. E., & Hauser, E. R. (2019). Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. *Human Genetics*, *125*(2), 217–229. https://doi.org/10.1007/s00439-008-0619-0

Douglas, G., & Channon, K. M. (2014). The pathogenesis of atherosclerosis. *Medicine*, 1–5. https://doi.org/10.1016/j.mpmed.2014.06.011

Drazen, J. M., Yandava, C. N., Dubé, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N., Silverman, E. S., Katz, D. A., & Drajesk, J. (1999). Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. *Nature Genetics*, *22*(2), 168–170. https://doi.org/10.1038/9680

Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., & Mehrabian, M. (2014). Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis. *New England Journal of Medicine*, *350*(1), 29–37. https://doi.org/10.1056/nejmoa025079

Feinberg, M. W., Shimizu, K., Lebedeva, M., Haspel, R., Takayama, K., Chen, Z., Frederick, J. P., Wang, X., Simon, D. I., Libby, P., Mitchell, R. N., & Jain, M. K. (2004). *and Vascular Inflammation*. https://doi.org/10.1161/01.RES.0000119170.70818.4F

Ferdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F., & Schulz, R. (2014). *Interaction of Risk Factors , Comorbidities , and Comedications with Ischemia / Reperfusion Injury and Cardioprotection by Preconditioning , Postconditioning , and Remote Conditioning* (Issue October).

Frank, D., Johnson, J., & De Caestecker, M. (2005). Bone morphogenetic protein 4 promotes vascular remodeling in hypoxic pulmonary hypertension. *Chest*, *128*(6 SUPPL.), 590S-591S. https://doi.org/10.1378/chest.128.6_suppl.590S

Fredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A., Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer, E. J., Spite, M., & Tabas, I. (2016). An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. *Nature Communications*, *7*, 1–11. https://doi.org/10.1038/ncomms12859

Funk, C. D., Hoshiko, S., Matsumoto, T., Radmark, O., & Samuelsson, B. (1989). Characterization of the human 5-lipoxygenase gene. *Proceedings of the National Academy of Sciences of the United States of America*, *86*(8), 2587–2591. https://doi.org/10.1073/pnas.86.8.2587

Gammelmark, A., Nielsen, M. S., Lundbye-Christensen, S., Tjønneland, A., Schmidt, E. B., & Overvad, K. (2015). Common polymorphisms in the 5-Lipoxygenase pathway and risk of incident myocardial infarction: A danish case-cohort study. *PLoS ONE*, *11*(11), 1–19. https://doi.org/10.1371/journal.pone.0167217

Gao, X., Starmer, J., & Martin, E. R. (2008). A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. *Genetic Epidemiology*, *32*(4), 361–369. https://doi.org/10.1002/gepi.20310

Iovannisci, D. M., Lammer, E. J., Steiner, L., Cheng, S., Mahoney, L. T., Davis, P. H., Lauer, R. M., & Burns, T. L. (2007). Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: The Muscatine study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *27*(2), 394–399. https://doi.org/10.1161/01.ATV.0000252680.72734.10

Jin, S., Choi, E. J., Choi, Y. J., Min, W. K., Park, J. Y., & Yoon, S. Z. (2023). Relationship between Arachidonate 5-Lipoxygenase-Activating Protein Gene and Peripheral Arterial Disease in Elderly Patients Undergoing General Surgery: A Retrospective Observational Study. *International Journal of Environmental Research and Public Health*, *20*(2). https://doi.org/10.3390/ijerph20021027

Knutsson, A., Björkbacka, H., Dunér, P., Engström, G., Binder, C. J., Nilsson, A. H., & Nilsson, J. (2019). Associations of Interleukin-5 With Plaque Development and Cardiovascular Events. *JACC: Basic to Translational Science*, *4*(8), 891–902. https://doi.org/10.1016/j.jacbts.2019.07.002

Koch, M., & Zernecke, A. (2014). The hemostatic system as a regulator of inflammation in atherosclerosis. *IUBMB Life*, *66*(11), 735–744. https://doi.org/10.1002/iub.1333

Kwon, G. P., Schroeder, J. L., Amar, M. J., Remaley, A. T., & Balaban, R. S. (2008). *Contribution of Macromolecular Structure to the Retention of Low-Density Lipoprotein at Arterial Branch Points*. *Ldl*, 2919–2927. https://doi.org/10.1161/CIRCULATIONAHA.107.754614

Linsel-Nitschke, P., Götz, A., Medack, A., König, I. R., Bruse, P., Lieb, W., Mayer, B., Stark, K., Hengstenberg, C., Fischer, M., Baessler, A., Ziegler, A., Schunkert, H., & Erdmann, J. (2018). Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP)is associated with myocardial infarction in the German population. *Clinical Science*, *115*(10), 309–315. https://doi.org/10.1042/CS20070468

Medina-leyte, D. J., Zepeda-garc, O., & Dom, M. (2021). *Endothelial Dysfunction , Inflammation and Coronary Artery Disease : Potential Biomarkers and Promising Therapeutical Approaches and new pharmacological and non-pharmacological*

promising th The endothelium is formed by a single layer of EC located about 1.

Mehrabian, M., & Allayee, H. (2003). *5-Lipoxygenase and atherosclerosis*. 447–457. https://doi.org/10.1097/01.mol.0000092617.86399.95

Mehrabian, M., Allayee, H., Wong, J., Shih, W., Wang, X. P., Shaposhnik, Z., Funk, C. D., & Lusis, A. J. (2002). Identification of 5-Lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. *Circulation Research*, *91*(2), 120–126. https://doi.org/10.1161/01.RES.0000028008.99774.7F

Mehu, M., Narasimhulu, C. A., & Singla, D. K. (2022). *Inflammatory Cells in Atherosclerosis*.

Montero, A., Nassar, G. M., Uda, S. J. Munger, K. A., & Badr, K. F. (2000). Reciprocal regulation of LTA4 hydrolase expression in human monocytes by γ-interferon and interleukins 4 and 13: Potential relevance to leukotriene regulation in glomerular disease. *Experimental Nephrology*, *8*(4–5), 258–265. https://doi.org/10.1159/000020677

Musumeci, M. (2009). Effect of LDL-apheresis on plasma lipids, chitotriosidase and anti-oxLDL antibodies in heterozygous familial hypercholes-terolemia. *Journal of Biomedical Science and Engineering*, *02*(07), 499–505. https://doi.org/10.4236/jbise.2009.25043

O'Brien, E. R., Urieli-Shoval, S., Garvin, M. R., Stewart, D. K., Hinohara, T., Simpson, J. B., Bendit, E. P., & Schwartz, S. M. (2000). Replication in restenotic atherectomy tissue. *Atherosclerosis*, *152*(1), 117–126. https://doi.org/10.1016/S0021-9150(99)00457-8

O'Leary, D. H., & Polak, J. F. (2002). Intima-media thickness: A tool for atherosclerosis imaging and event prediction. *American Journal of Cardiology*, *90*(10 SUPPL. 3), L18–L21. https://doi.org/10.1016/s0002-9149(02)02957-0

Owens, G. K., Kumar, M. S., & Wamhoff, B. R. (2004). Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiological Reviews*, *84*(3), 767–801. https://doi.org/10.1152/physrev.00041.2003

Ozaki, K., & Tanaka, T. (2016). Molecular genetics of coronary artery disease. *Journal of Human Genetics*, *61*(1), 71–77. https://doi.org/10.1038/jhg.2015.70

Pardali, E., & Dijke, P. (2012). *TGF Signaling and Cardiovascular Diseases*. https://doi.org/10.7150/ijbs.3805

Robertson, A. L., Flavell, R. A., Hansson, G. K., Robertson, A. L., Rudling, M., Zhou, X., Gorelik, L., Flavell, R. A., & Hansson, G. K. (2003). *Disruption of TGF-β signaling in T cells accelerates atherosclerosis Find the latest version : Disruption of TGF- β signaling in T cells accelerates atherosclerosis*. *112*(9), 1342–1350. https://doi.org/10.1172/JCI200318607.Introduction

Roy, P., Orecchioni, M., & Ley, K. (2022). How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. *Nature Reviews Immunology*, *22*(4), 251–265. https://doi.org/10.1038/s41577-021-00584-1

Sasaki, F., & Yokomizo, T. (2019). The leukotriene receptors as therapeutic targets of inflammatory diseases. *International Immunology*, *31*(9), 607–615. https://doi.org/10.1093/intimm/dxz044

Singh, N. N., & Ramji, D. P. (2006). The role of transforming growth factor-β in atherosclerosis. *Cytokine and Growth Factor Reviews*, *17*(6), 487–499. https://doi.org/10.1016/j.cytogfr.2006.09.002

Sivanand. (2019). Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects. *Physiology & Behavior*, *176*(3), 139–148. https://doi.org/10.1007/s00441-011-1189-3.Transforming

Sweatt,S.K, Gower, B.A, Chieh, A.Y, Liu, Y, Li, L. (2016). 乳鼠心肌提取 HHS Public Access. *Physiology & Behavior*, *176*(1), 139–148. https://doi.org/10.1016/j.gene.2015.07.073.Structural

Todur, S. P., & Ashavaid, T. F. (2012). Association of Sp1 Tandem Repeat Polymorphism of ALOX5 with Coronary Artery Disease in Indian Subjects. *Clinical and Translational Science*, *5*(5), 408–411. https://doi.org/10.1111/j.1752-8062.2011.00396.x

Yamada, Y., Komaki, S., & Nishida, T. (2018). Molecular genetics of myocardial infarction. *Genomic Medicine*, *2*(1–2), 7–22. https://doi.org/10.1007/s11568-008-9025-x

Yangguang Du, Rachael E Wilson, and S. G. W. (2018). 乳鼠心肌提取 HHS Public Access. *Annu Rev Anal Chem (Palo Alto Calif)*, *11*(1), 509–533. https://doi.org/10.1161/CIRCGENETICS.113.000152.A

Ye, H., Zhang, X., Chen, Z., Li, X., Zhang, T., Yang, C., & Huang, L. (2018). *Association between the polymorphism (rs17222919, À 1316T/G) of 5-lipoxygenase- activating protein gene (ALOX5AP) and the risk of stroke*. *March*, 1–6.

Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., & Wei, Q. (2022). Signaling pathways and targeted therapy for myocardial infarction. *Signal Transduction and Targeted Therapy*, *7*(1). https://doi.org/10.1038/s41392-022-00925-z

Azzi, A., Breyer, I., Feher, M., Pastori, M., Ricciarelli, R., Spycher, S., Staffieri, M., Stocker, A., Zimmer, S., & Zingg, J. (2018). *Recent Advances in Nutritional Sciences*. *April*, 1649–1652.

Chen, P., Qin, L., Li, G., Wang, Z., Dahlman, J. E., Malagon-lopez, J., Gujja, S., Cilfone, N. A., Kauffman, K. J., Kusters, P., Sehgal, A., Jiao, Y., Anderson, D. G., & Gulcher, J. (2022). inflammation and atherosclerosis. *Nature Metabolism*. https://doi.org/10.1038/s42255-019-0102-3

Cipollone, F., Mezzetti, A., Fazia, M. L., Cuccurullo, C., Iezzi, A., Ucchino, S., Spigonardo, F., Bucci, M., Cuccurullo, F., Prescott, S. M., & Stafforini, D. M. (2015). Association between 5-lipoxygenase expression and plaque instability in humans. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *25*(8), 1665–1670. https://doi.org/10.1161/01.ATV.0000172632.96987.2d

Colazzo, F., Gelosa, P., Tremoli, E., Sironi, L., & Castiglioni, L. (2017a). Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases. *Mediators of Inflammation*, *2017*(Figure 1). https://doi.org/10.1155/2017/2432958

Colazzo, F., Gelosa, P., Tremoli, E., Sironi, L., & Castiglioni, L. (2017b). Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases. *Mediators of Inflammation*, *2017*(Figure 1). https://doi.org/10.1155/2017/2432958

Crosslin, D. R., Shah, S. H., Nelson, S. C., Haynes, C. S., Connelly, J. J., Gadson, S., Goldschmidt-Clermont, P. J., Vance, J. M., Rose, J., Granger, C. B., Seo, D., Gregory, S. G., Kraus, W. E., & Hauser, E. R. (2019). Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. *Human Genetics*, *125*(2), 217–229.

https://doi.org/10.1007/s00439-008-0619-0

Douglas, G., & Channon, K. M. (2014). The pathogenesis of atherosclerosis. *Medicine*, 1–5. https://doi.org/10.1016/j.mpmed.2014.06.011

Drazen, J. M., Yandava, C. N., Dubé, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N., Silverman, E. S., Katz, D. A., & Drajesk, J. (1999). Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. *Nature Genetics*, *22*(2), 168–170. https://doi.org/10.1038/9680

Dwyer, J. H., Allayee, H., Dwyer, K. M., Fan, J., Wu, H., Mar, R., Lusis, A. J., & Mehrabian, M. (2014). Arachidonate 5-Lipoxygenase Promoter Genotype, Dietary Arachidonic Acid, and Atherosclerosis. *New England Journal of Medicine*, *350*(1), 29–37. https://doi.org/10.1056/nejmoa025079

Feinberg, M. W., Shimizu, K., Lebedeva, M., Haspel, R., Takayama, K., Chen, Z., Frederick, J. P., Wang, X., Simon, D. I., Libby, P., Mitchell, R. N., & Jain, M. K. (2004). *and Vascular Inflammation*. https://doi.org/10.1161/01.RES.0000119170.70818.4F

Ferdinandy, P., Hausenloy, D. J., Heusch, G., Baxter, G. F., & Schulz, R. (2014). *Interaction of Risk Factors , Comorbidities , and Comedications with Ischemia / Reperfusion Injury and Cardioprotection by Preconditioning , Postconditioning , and Remote Conditioning* (Issue October).

Frank, D., Johnson, J., & De Caestecker, M. (2005). Bone morphogenetic protein 4 promotes vascular remodeling in hypoxic pulmonary hypertension. *Chest*, *128*(6 SUPPL.), 590S-591S. https://doi.org/10.1378/chest.128.6_suppl.590S

Fredman, G., Hellmann, J., Proto, J. D., Kuriakose, G., Colas, R. A., Dorweiler, B., Connolly, E. S., Solomon, R., Jones, D. M., Heyer, E. J., Spite, M., & Tabas, I. (2016). An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. *Nature Communications*, *7*, 1–11. https://doi.org/10.1038/ncomms12859

Funk, C. D., Hoshiko, S., Matsumoto, T., Radmark, O., & Samuelsson, B. (1989). Characterization of the human 5-lipoxygenase gene. *Proceedings of the National Academy of Sciences of the United States of America*, *86*(8), 2587–2591. https://doi.org/10.1073/pnas.86.8.2587

Gammelmark, A., Nielsen, M. S., Lundbye-Christensen, S., Tjønneland, A., Schmidt, E. B., & Overvad, K. (2016). Common polymorphisms in the 5-Lipoxygenase pathway and risk of incident myocardial infarction: A danish case-cohort study. *PLoS ONE*, *11*(11), 1–19. https://doi.org/10.1371/journal.pone.0167217

Gao, X., Starmer, J., & Martin, E. R. (2008). A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. *Genetic Epidemiology*, *32*(4), 361–369. https://doi.org/10.1002/gepi.20310

Iovannisci, D. M., Lammer, E. J., Steiner, L., Cheng, S., Mahoney, L. T., Davis, P. H., Lauer, R. M., & Burns, T. L. (2007). Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: The Muscatine study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *27*(2), 394–399. https://doi.org/10.1161/01.ATV.0000252680.72734.10

Jin, S., Choi, E. J., Choi, Y. J., Min, W. K., Park, J. Y., & Yoon, S. Z. (2023). Relationship

between Arachidonate 5-Lipoxygenase-Activating Protein Gene and Peripheral Arterial Disease in Elderly Patients Undergoing General Surgery: A Retrospective Observational Study. *International Journal of Environmental Research and Public Health*, *20*(2). https://doi.org/10.3390/ijerph20021027

Knutsson, A., Björkbacka, H., Dunér, P., Engström, G., Binder, C. J., Nilsson, A. H., & Nilsson, J. (2019). Associations of Interleukin-5 With Plaque Development and Cardiovascular Events. *JACC: Basic to Translational Science*, *4*(8), 891–902. https://doi.org/10.1016/j.jacbts.2019.07.002

Koch, M., & Zernecke, A. (2014). The hemostatic system as a regulator of inflammation in atherosclerosis. *IUBMB Life*, *66*(11), 735–744. https://doi.org/10.1002/iub.1333

Kwon, G. P., Schroeder, J. L., Amar, M. J., Remaley, A. T., & Balaban, R. S. (2008). *Contribution of Macromolecular Structure to the Retention of Low-Density Lipoprotein at Arterial Branch Points*. *Ldl*, 2919–2927. https://doi.org/10.1161/CIRCULATIONAHA.107.754614

Linsel-Nitschke, P., Götz, A., Medack, A., König, I. R., Bruse, P., Lieb, W., Mayer, B., Stark, K., Hengstenberg, C., Fischer, M., Baessler, A., Ziegler, A., Schunkert, H., & Erdmann, J. (2008). Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP)is associated with myocardial infarction in the German population. *Clinical Science*, *115*(10), 309–315. https://doi.org/10.1042/CS20070468

Medina-leyte, D. J., Zepeda-garc, O., & Dom, M. (2021). *Endothelial Dysfunction , Inflammation and Coronary Artery Disease : Potential Biomarkers and Promising Therapeutical Approaches and new pharmacological and non-pharmacological promising th The endothelium is formed by a single layer of EC located about 1*.

Mehrabian, M., & Allayee, H. (2003). *5-Lipoxygenase and atherosclerosis*. 447–457. https://doi.org/10.1097/01.mol.0000092617.86399.95

Mehrabian, M., Allayee, H., Wong, J., Shih, W., Wang, X. P., Shaposhnik, Z., Funk, C. D., & Lusis, A. J. (2002). Identification of 5-Lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. *Circulation Research*, *91*(2), 120–126. https://doi.org/10.1161/01.RES.0000028008.99774.7F

Mehu, M., Narasimhulu, C. A., & Singla, D. K. (2022). *Inflammatory Cells in Atherosclerosis*.

Montero, A., Nassar, G. M., Uda, S., Munger, K. A., & Badr, K. F. (2000). Reciprocal regulation of LTA4 hydrolase expression in human monocytes by γ-interferon and interleukins 4 and 13: Potential relevance to leukotriene regulation in glomerular disease. *Experimental Nephrology*, *8*(4–5), 258–265. https://doi.org/10.1159/000020677

Musumeci, M. (2009). Effect of LDL-apheresis on plasma lipids, chitotriosidase and anti-oxLDL antibodies in heterozygous familial hypercholes-terolemia. *Journal of Biomedical Science and Engineering*, *02*(07), 499–505. https://doi.org/10.4236/jbise.2009.25043

O'Brien, E. R., Urieli-Shoval, S., Garvin, M. R., Stewart, D. K., Hinohara, T., Simpson, J. B., Benditt, E. P., & Schwartz, S. M. (2000). Replication in restenotic atherectomy tissue. *Atherosclerosis*, *152*(1), 117–126. https://doi.org/10.1016/S0021-9150(99)00457-8

O'Leary, D. H., & Polak, J. F. (2002). Intima-media thickness: A tool for atherosclerosis imaging and event prediction. *American Journal of Cardiology*, *90*(10 SUPPL. 3), L18–L21. https://doi.org/10.1016/s0002-9149(02)02957-0

Owens, G. K., Kumar, M. S., & Wamhoff, B. R. (2004). Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiological Reviews*, *84*(3), 767–801. https://doi.org/10.1152/physrev.00041.2003

Ozaki, K., & Tanaka, T. (2016). Molecular genetics of coronary artery disease. *Journal of Human Genetics*, *61*(1), 71–77. https://doi.org/10.1038/jhg.2015.70

Pardali, E., & Dijke, P. (2012). *TGF Signaling and Cardiovascular Diseases*. https://doi.org/10.7150/ijbs.3805

Robertson, A. L., Flavell, R. A., Hansson, G. K., Robertson, A. L., Rudling, M., Zhou, X., Gorelik, L., Flavell, R. A., & Hansson, G. K. (2003). *Disruption of TGF-β signaling in T cells accelerates atherosclerosis Find the latest version : Disruption of TGF-β signaling in T cells accelerates atherosclerosis*. *112*(9), 1342–1350. https://doi.org/10.1172/JCI200318607.Introduction

Roy, P., Orecchioni, M., & Ley, K. (2022). How the immune system shapes atherosclerosis: roles of innate and adaptive immunity. *Nature Reviews Immunology*, *22*(4), 251–265. https://doi.org/10.1038/s41577-021-00584-1

Sasaki, F., & Yokomizo, T. (2019). The leukotriene receptors as therapeutic targets of inflammatory diseases. *International Immunology*, *31*(9), 607–615. https://doi.org/10.1093/intimm/dxz044

Singh, N. N., & Ramji, D. P. (2006). The role of transforming growth factor-β in atherosclerosis. *Cytokine and Growth Factor Reviews*, *17*(6), 487–499. https://doi.org/10.1016/j.cytogfr.2006.09.002

Sivanand, S. (2019). Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects. *Physiology & Behavior*, *176*(3), 139–148. https://doi.org/10.1007/s00441-011-1189-3.Transforming

Sweatt,S. K, Gower, B.A, Chieh, A.Y, Liu, Y, Li, L. (2016). 乳鼠心肌提取 HHS Public Access. *Physiology & Behavior*, *176*(1), 139–148. https://doi.org/10.1016/j.gene.2015.07.073.Structural

Todur, S. P., & Ashavaid, T. F. (2012). Association of Sp1 Tandem Repeat Polymorphism of ALOX5 with Coronary Artery Disease in Indian Subjects. *Clinical and Translational Science*, *5*(5), 408–411. https://doi.org/10.1111/j.1752-8062.2011.00396.x

Yamada, Y., Ichihara, S., & Nishida, T. (2018). Molecular genetics of myocardial infarction. *Genomic Medicine*, *2*(1–2), 7–22. https://doi.org/10.1007/s11568-008-9025-x

Yangguang Ou, Rachael E Wilson, and S. G. W. (2018). 乳鼠心肌提取 HHS Public Access. *Annu Rev Anal Chem (Palo Alto Calif)*, *11*(1), 509–533. https://doi.org/10.1161/CIRCGENETICS.113.000152.A

Ye, H., Zhang, X., Chen, Z., Li, X., Zhang, T., Yang, C., & Huang, L. (2018). *Association between the polymorphism (rs17222919, À 1316T/G) of 5-lipoxygenase- activating protein gene (ALOX5AP) and the risk of stroke*. *March*, 1–6.

Zhang, Q., Wang, L., Wang, S., Cheng, H., Xu, L., Pei, G., Wang, Y., Fu, C., Jiang, Y., He, C., & Wei, Q. (2022). Signaling pathways and targeted therapy for myocardial infarction. *Signal Transduction and Targeted Therapy*, *7*(1). https://doi.org/10.1038/s41392-022-00925-z


UNIVERSITAS ANDALAS
UNTUK
KEDJAJAAN
BANGSA